1. Home
  2. ACGLN vs KPTI Comparison

ACGLN vs KPTI Comparison

Compare ACGLN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACGLN
  • KPTI
  • Stock Information
  • Founded
  • ACGLN N/A
  • KPTI 2008
  • Country
  • ACGLN Bermuda
  • KPTI United States
  • Employees
  • ACGLN 5800
  • KPTI N/A
  • Industry
  • ACGLN Property-Casualty Insurers
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACGLN Finance
  • KPTI Health Care
  • Exchange
  • ACGLN Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • ACGLN N/A
  • KPTI 33.6M
  • IPO Year
  • ACGLN N/A
  • KPTI 2013
  • Fundamental
  • Price
  • ACGLN $17.13
  • KPTI $5.62
  • Analyst Decision
  • ACGLN
  • KPTI Strong Buy
  • Analyst Count
  • ACGLN 0
  • KPTI 5
  • Target Price
  • ACGLN N/A
  • KPTI $61.00
  • AVG Volume (30 Days)
  • ACGLN N/A
  • KPTI 135.2K
  • Earning Date
  • ACGLN N/A
  • KPTI 05-07-2025
  • Dividend Yield
  • ACGLN N/A
  • KPTI N/A
  • EPS Growth
  • ACGLN N/A
  • KPTI N/A
  • EPS
  • ACGLN N/A
  • KPTI N/A
  • Revenue
  • ACGLN N/A
  • KPTI $145,237,000.00
  • Revenue This Year
  • ACGLN N/A
  • KPTI $4.87
  • Revenue Next Year
  • ACGLN N/A
  • KPTI $16.29
  • P/E Ratio
  • ACGLN N/A
  • KPTI N/A
  • Revenue Growth
  • ACGLN N/A
  • KPTI N/A
  • 52 Week Low
  • ACGLN N/A
  • KPTI $3.51
  • 52 Week High
  • ACGLN N/A
  • KPTI $18.00
  • Technical
  • Relative Strength Index (RSI)
  • ACGLN 45.69
  • KPTI 53.53
  • Support Level
  • ACGLN $17.04
  • KPTI $3.83
  • Resistance Level
  • ACGLN $17.33
  • KPTI $6.56
  • Average True Range (ATR)
  • ACGLN 0.35
  • KPTI 0.48
  • MACD
  • ACGLN 0.08
  • KPTI 0.34
  • Stochastic Oscillator
  • ACGLN 73.50
  • KPTI 68.67

About ACGLN Arch Capital Group Ltd.

Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: